文献

J-GLOBAL ID：202202226184004577   整理番号：22A1026730

色素嫌性腎細胞癌の高齢患者における競合リスクモデルの開発と検証:集団ベース研究【JST・京大機械翻訳】

Development and Validation of a Competitive Risk Model in Elderly Patients With Chromophobe Cell Renal Carcinoma: A Population-Based Study

著者 (65件)： Wang Jinkui (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Wang Jinkui (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Wang Jinkui (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Wang Jinkui (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Wang Jinkui (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Wang Jinkui (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Wang Jinkui (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Zhanghuang Chenghao (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Zhanghuang Chenghao (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Zhanghuang Chenghao (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Zhanghuang Chenghao (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Zhanghuang Chenghao (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Zhanghuang Chenghao (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Zhanghuang Chenghao (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Zhanghuang Chenghao (Department of Urology, Kunming Children’s Hospital, Kunming, China) ,  Zhanghuang Chenghao (Yunnan Provincial Key Research Laboratory of Pediatric Major Diseases, Kunming, China) ,  Tan Xiaojun (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Tan Xiaojun (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Tan Xiaojun (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Tan Xiaojun (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Tan Xiaojun (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Tan Xiaojun (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Tan Xiaojun (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Mi Tao (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Mi Tao (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Mi Tao (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Mi Tao (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Mi Tao (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Mi Tao (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Mi Tao (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Liu Jiayan (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Liu Jiayan (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Liu Jiayan (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Liu Jiayan (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Liu Jiayan (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Liu Jiayan (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Liu Jiayan (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Jin Liming (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Jin Liming (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Jin Liming (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Jin Liming (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Jin Liming (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Jin Liming (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Jin Liming (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Li Mujie (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Li Mujie (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Li Mujie (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Li Mujie (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Li Mujie (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Li Mujie (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Li Mujie (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Zhang Zhaoxia (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  Zhang Zhaoxia (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  Zhang Zhaoxia (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  Zhang Zhaoxia (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  Zhang Zhaoxia (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  Zhang Zhaoxia (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  Zhang Zhaoxia (Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  He Dawei (Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China) ,  He Dawei (Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Chongqing, China) ,  He Dawei (Chongqing Key Laboratory of Pediatrics, Chongqing, China) ,  He Dawei (Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China) ,  He Dawei (National Clinical Research Center for Child Health and Disorders, Chongqing, China) ,  He Dawei (China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China) ,  He Dawei (Children’s Hospital of Chongqing Medical University, Chongqing, China)
資料名： Frontiers in Public Health (Web)  (Frontiers in Public Health (Web))
巻： 10  ページ： 840525  発行年： 2022年 
JST資料番号： U7097A  ISSN： 2296-2565  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： スイス (CHE)  言語： 英語 (EN)

抄録/ポイント： 背景:腎細胞癌(RCC)は,成人で最も一般的な腎悪性腫瘍であり,クロモホア腎細胞癌(chRCC)はRCCの3番目に一般的なサブタイプである。chRCCの高齢患者における癌特異的生存(CSS)を予測するための競合リスクモデルの構築を目的とした。方法:患者の臨床病理学的情報をSEERデータベースからダウンロードし,患者を訓練と検証コホートにランダムに分けた。癌特異的死亡(CSM)に対する患者の危険因子を,比例サブ分布ハザード(SH)を用いて分析した。高齢のchRCC患者のCSSを予測するための競合リスクモデルを構築した。一貫性指数(C指数),受信者動作特性曲線下面積(AUC),および較正曲線を用いて,モデルの精度を検証した。決定曲線分析(DCA)を用いて,モデルの臨床的価値を試験した。結果:chRCCを有する合計3522人の高齢患者を分析に含めた。患者を訓練コホート(N=2,474)または検証コホート(N=1,048)のいずれかに無作為に割り当てた。SH分析は,年齢,人種,T,N,およびM期,腫瘍サイズ,および手術がCSMの危険因子であることを示した。患者のCSSを予測する競合リスクモデルを構築した。訓練セットにおいて,モデルは,それぞれ,82.2,80.8,および78.2のC-indicesで,患者の1,3-,および5年CSSを予測した。モデルは,それぞれ,84.7,83.4,および76.9のC-indicesを有する検証コホートにおいて,患者1,3-および5年CSSを予測した。較正曲線は,モデルの予測値が観測値とほぼ一致し,モデルが良好な精度を有することを示した。訓練セットと検証待ち行列のAUCも,モデルが良好な識別を持つことを示唆した。患者のCSSの予測におけるDCAモデルの臨床的有用性は,従来のTNM分類のそれより高い。結論:chRCCの高齢患者におけるCSSを予測するための競合リスクモデルを作成した。モデルは良好な精度と信頼性を持ち,医師と患者が臨床決定と追跡調査戦略を作るのを助けることができる。Copyright 2022 The Author(s) All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 信頼性 ,  データベース ,  *腎臓 ,  死 ,  *色素 ,  *腫瘍 ,  発色団 ,  検量線 ,  *患者 ,  母集団 ,  *腎細胞癌 ,  TNM分類 ,  危険因子
準シソーラス用語： 悪性腫瘍 ,  腫瘍サイズ ,  予測値 , 【Automatic Indexing@JST】

著者キーワード (5件)： 競争リスクモデル ,  ノモグラム ,  高齢者 ,  色素嫌性腎細胞癌 ,  SEER

分類 (1件)： 泌尿生殖器の腫よう  (GM04000S)

引用文献 (46件)：

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394-424. doi: 10.3322/caac.21492
• Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. (2016) 70:106-19. doi: 10.1016/j.eururo.2016.02.028
• Badowska-Kozakiewicz AM, Budzik MP, Koczkodaj P, Przybylski J. Selected tumor markers in the routine diagnosis of chromophobe renal cell carcinoma. Arch Med Sci. (2016) 12:856-63. doi: 10.5114/aoms.2015.51188
• Jia W, Hu C, Xu J, Ming J, Zhao Y, Cai M, et al. Dissolved organic matter derived from rape straw pretreated with selenium in soil improves the inhibition of Sclerotinia sclerotiorum growth. J Hazard Mater. (2019) 369:601-10. doi: 10.1016/j.jhazmat.2019.02.055
• Maroto P, Anguera G, Roldan-Romero JM, Apellániz-Ruiz M, Algaba F, Boonman J, et al. Biallelic TSC2 mutations in a patient with chromophobe renal cell carcinoma showing extraordinary response to temsirolimus. J Natl Compr Canc Netw. (2018) 16:352-8. doi: 10.6004/jnccn.2017.7041

タイトルに関連する用語 (10件)： 色素 ,  腎細胞癌 ,  高齢患者 ,  競合 ,  リスク ,  モデル ,  開発 ,  検証 ,  集団 ,  研究